DOP022 Vedolizumab and anti-TNFα treatment effectiveness in patients with IBD treated in Germany: a retrospective chart review

Background: Vedolizumab (VDZ) is a gut-selective monoclonal anti-integrin antibody indicated for the treatment (Tx) of moderate-to-severe Crohn's disease (CD) and ulcerative colitis (UC). Real-world outcomes in patients who received VDZ as 1st/2nd line biologic is limited. This study evaluated VDZ Tx patterns/effectiveness in Germany in comparison to anti-TNFα. Methods: This was a descriptive retrospective chart review study of CD and UC...